https://www.selleckchem.com/GSK-3.html
Less than one quarter were female. In the first year following treatment, women had worse OS and RS than men (p=0.093 and p=0.030, respectively). However, overall and relative survival differences between sexes were not statistically significantly different in Years 2 and later. Unlike with OS, the RS between sexes remained significant at 9years; in multivariable analysis based on RS, women were 43% more likely to die than men (p0.001). Women had a higher initial risk of death than men in the first year following TMT. However, long-term surviv
Like
Comment
Share
